Business Standard

Tuesday, December 24, 2024 | 04:54 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Lupin alliance partner Concord gets USFDA nod for generic medicine

Concord has received approval from the US Food and Drug Administration (USFDA) to market the drug to prevent organ transplant rejection

lupin
Premium

As per IQVIA MAT March 2020 data, Mycophenolate Mofetil Tablets USP, 500 mg had annual sales of around $96 million in the US.

Press Trust of India New Delhi
Drugmaker Lupin on Thursday said its partner Concord Biotech has received approval from the US health regulator to market Mycophenolate Mofetil tablets, used to prevent organ transplant rejection.

Concord has received approval from the US Food and Drug Administration (USFDA) to market the product, which is a generic version of Roche Palo Alto's CellCept tablets, Lupin Ltd said in a statement.

Mycophenolate Mofetil tablets are indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants, it added.

As per IQVIA MAT March 2020 data, Mycophenolate Mofetil Tablets USP, 500

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in